tbuckley/cabot-search huggingface dataset:
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Authors: Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Alexis Castaneda Puglianini
Journal: Blood Cancer Journal (2023)

Abstract Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.
Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis
Authors: Tomohiko Yamada, Nobuhiro Hiramoto, Takuto Mori, Daisuke Yamashita, Yukimasa Tai, Ryusuke Yamamoto, Masashi Nishikubo, Hayato Maruoka, Kana Sakamoto, Kengo Takeuchi, Yasuhito Nannya, Seishi Ogawa, Takayuki Ishikawa
Journal: Blood Cancer Journal (2023)
Multiomics of three hematological malignancies in a patient reveal their origin from clonal hematopoietic stem cells
Authors: Sylvain Mayeur, Anne Molitor, Laurent Miguet, Lucie Rigolot, Lydie Naegely, Tristan Stemmelen, Sébastien Meyer, Elise Toussaint, Laurent Vallat, Alice Eischen, Marie-Pierre Chenard, Manuela Tavian, Seiamak Bahram, Raphael Carapito, Alina Nicolae
Journal: Blood Cancer Journal (2023)
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification
Authors: Wan-Hsuan Lee, Ming-Tao Tsai, Cheng-Hong Tsai, Feng-Ming Tien, Min-Yen Lo, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Ming-Chih Liu, Yi-Tsung Yang, Jui-Che Chen, Jih-Luh Tang, Hsun-I Sun, Yi-Kuang Chuang, Liang-In Lin, Wen-Chien Chou, Chien-Chin Lin, Hsin-An Hou, Hwei-Fang Tien
Journal: Blood Cancer Journal (2023)

Myelodysplastic syndromes (MDS) have varied prognoses and require a risk-adapted treatment strategy for treatment optimization. Recently, a molecular prognostic model (Molecular International Prognostic Scoring System [IPSS-M]) that combines clinical parameters, cytogenetic abnormalities, and mutation topography was proposed. This study validated the IPSS-M in 649 patients with primary MDS (based on the 2022 International Consensus Classification [ICC]) and compared its prognostic power to those of the IPSS and revised IPSS (IPSS-R). Overall, 42.5% of the patients were reclassified and 29.3% were up-staged from the IPSS-R. After the reclassification, 16.9% of the patients may receive different treatment strategies. The IPSS-M had greater discriminative potential than the IPSS-R and IPSS. Patients with high, or very high-risk IPSS-M might benefit from allogeneic hematopoietic stem cell transplantation. IPSS-M, age, ferritin level, and the 2022 ICC categorization predicted outcomes independently. After analyzing demographic and genetic features, complementary genetic analyses, including KMT2A-PTD, were suggested for accurate IPSS-M categorization of patients with ASXL1, TET2, STAG2, RUNX1, SF3B1, SRSF2, DNMT3A, U2AF1, and BCOR mutations and those classified as MDS, not otherwise specified with single lineage dysplasia/multi-lineage dysplasia based on the 2022 ICC. This study confirmed that the IPSS-M can better risk-stratified MDS patients for optimized therapeutic decision-making.
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma
Authors: Marco Tagliamento, Massimo Di Maio, Jordi Remon, Paolo Bironzo, Carlo Genova, Francesco Facchinetti, Mihaela Aldea, Cécile Le Péchoux, Silvia Novello, Fabrice Barlesi, Benjamin Besse, David Planchard
Journal: Journal of Thoracic Oncology (2023)
Converging evidence from exome sequencing and common variants implicates target genes for osteoporosis
Authors: Sirui Zhou, Olukayode A Sosina, Jonas Bovijn, Laetitia Laurent, Vasundhara Sharma, Parsa Akbari, Vincenzo Forgetta, Lai Jiang, Jack A Kosmicki, Nilanjana Banerjee, John A Morris, Erin Oerton, Marcus Jones, Michelle G LeBlanc, Vincent Idone, John D Overton, Jeffrey G Reid, Michael Cantor, Goncalo R Abecasis, David Goltzman, Celia M T Greenwood, Claudia Langenberg, Aris Baras, Aris N Economides, Manuel A R Ferreira, Sarah Hatsell, Claes Ohlsson, J Brent Richards, Luca A Lotta
Journal: Nature Genetics (2023)
MISPEL: A supervised deep learning harmonization method for multi-scanner neuroimaging data
Authors: Mahbaneh Eshaghzadeh Torbati, Davneet S. Minhas, Charles M. Laymon, Pauline Maillard, James D. Wilson, Chang-Le Chen, Ciprian M. Crainiceanu, Charles S. DeCarli, Seong Jae Hwang, Dana L. Tudorascu
Journal: Medical Image Analysis (2023)

Large-scale data obtained from aggregation of already collected multi-site neuroimaging datasets has brought benefits such as higher statistical power, reliability, and robustness to the studies. Despite these promises from growth in sample size, substantial technical variability stemming from differences in scanner specifications exists in the aggregated data and could inadvertently bias any downstream analyses on it. Such a challenge calls for data normalization and/or harmonization frameworks, in addition to comprehensive criteria to estimate the scanner-related variability and evaluate the harmonization frameworks. In this study, we propose MISPEL (Multi-scanner Image harmonization via Structure Preserving Embedding Learning), a supervised multi-scanner harmonization method that is naturally extendable to more than two scanners. We also designed a set of criteria to investigate the scanner-related technical variability and evaluate the harmonization techniques. As an essential requirement of our criteria, we introduced a multi-scanner matched dataset of 3T T1 images across four scanners, which, to the best of our knowledge is one of the few datasets of this kind. We also investigated our evaluations using two popular segmentation frameworks: FSL and segmentation in statistical parametric mapping (SPM). Lastly, we compared MISPEL to popular methods of normalization and harmonization, namely White Stripe, RAVEL, and CALAMITI. MISPEL outperformed these methods and is promising for many other neuroimaging modalities.
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Authors: Emanuel Raschi, Manuela Casula, Arrigo F.G. Cicero, Alberto Corsini, Claudio Borghi, Alberico Catapano
Journal: Pharmacology & Therapeutics (2023)

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial issue, not only in terms of the most appropriate therapeutic range for lipid levels, but also with regard to the optimal strategy and sequence approach (stepwise vs upstream therapy). Current treatment guidelines for the management of dyslipidemia focus on the intensity of low-density lipoprotein cholesterol (LDL-C) reduction, stratified according to risk for developing ASCVD. Beyond statins and ezetimibe, different medications targeting LDL-C have been recently approved by regulatory agencies with potential innovative mechanisms of action, including proprotein convertase subtilisin/kexin type 9 modulators (monoclonal antibodies such as evolocumab and alirocumab; small interfering RNA molecules such as inclisiran), ATP-citrate lyase inhibitors (bempedoic acid), angiopoietin-like 3 inhibitors (evinacumab), and microsomal triglyceride transfer protein inhibitors (lomitapide). An understanding of their pharmacological aspects, benefit-risk profile, including impact on hard cardiovascular endpoint beyond LDL-C reduction, and potential advantages from the patient perspective (e.g., adherence) - the focus of this evidence-based review - is crucial for practitioners across medical specialties to minimize therapeutic inertia and support clinical practice.
NK cell-based tumor immunotherapy
Authors: Hao Zhang, Li Yang, Tingting Wang, Zhen Li
Journal: Bioactive Materials (2023)

Natural killer (NK) cells display a unique inherent ability to identify and eliminate virus-infected cells and tumor cells. They are particularly powerful for elimination of hematological cancers, and have attracted considerable interests for therapy of solid tumors. However, the treatment of solid tumors with NK cells are less effective, which can be attributed to the very complicated immunosuppressive microenvironment that may lead to the inactivation, insufficient expansion, short life, and the poor tumor infiltration of NK cells. Fortunately, the development of advanced nanotechnology has provided potential solutions to these issues, and could improve the immunotherapy efficacy of NK cells. In this review, we summarize the activation and inhibition mechanisms of NK cells in solid tumors, and the recent advances in NK cell-based tumor immunotherapy boosted by diverse nanomaterials. We also propose the challenges and opportunities for the clinical application of NK cell-based tumor immunotherapy.
Hypoxia-inducing cryogels uncover key cancer-immune cell interactions in an oxygen-deficient tumor microenvironment
Authors: Thibault Colombani, Zachary J. Rogers, Khushbu Bhatt, James Sinoimeri, Lauren Gerbereux, Mohammad Hamrangsekachaee, Sidi A. Bencherif
Journal: Bioactive Materials (2023)

Hypoxia is a major factor shaping the immune landscape, and several cancer models have been developed to emulate hypoxic tumors. However, to date, they still have several limitations, such as the lack of reproducibility, inadequate biophysical cues, limited immune cell infiltration, and poor oxygen (O
Obesity-Related Hypogonadism in Women
Authors: Pei Chia Eng, Maria Phylactou, Ambreen Qayum, Casper Woods, Hayoung Lee, Sara Aziz, Benedict Moore, Alexander D Miras, Alexander N Comninos, Tricia Tan, Steve Franks, Waljit S Dhillo, Ali Abbara
Journal: Endocrine Reviews (2023)

Obesity-related hypogonadotropic hypogonadism is a well-characterized condition in men (termed male obesity-related secondary hypogonadism; MOSH); however, an equivalent condition has not been as clearly described in women. The prevalence of polycystic ovary syndrome (PCOS) is known to increase with obesity, but PCOS is more typically characterized by increased gonadotropin-releasing hormone (GnRH) (and by proxy luteinizing hormone; LH) pulsatility, rather than by the reduced gonadotropin levels observed in MOSH. Notably, LH levels and LH pulse amplitude are reduced with obesity, both in women with and without PCOS, suggesting that an obesity-related secondary hypogonadism may also exist in women akin to MOSH in men. Herein, we examine the evidence for the existence of a putative non-PCOS "female obesity-related secondary hypogonadism" (FOSH). We précis possible underlying mechanisms for the occurrence of hypogonadism in this context and consider how such mechanisms differ from MOSH in men, and from PCOS in women without obesity. In this review, we consider relevant etiological factors that are altered in obesity and that could impact on GnRH pulsatility to ascertain whether they could contribute to obesity-related secondary hypogonadism including: anti-Müllerian hormone, androgen, insulin, fatty acid, adiponectin, and leptin. More precise phenotyping of hypogonadism in women with obesity could provide further validation for non-PCOS FOSH and preface the ability to define/investigate such a condition.
Historic Sampling of a Vanishing Beast: Population Structure and Diversity in the Black Rhinoceros
Authors: Fátima Sánchez-Barreiro, Binia De Cahsan, Michael V Westbury, Xin Sun, Ashot Margaryan, Claudia Fontsere, Michael W Bruford, Isa-Rita M Russo, Daniela C Kalthoff, Thomas Sicheritz-Pontén, Bent Petersen, Love Dalén, Guojie Zhang, Tomás Marquès-Bonet, M Thomas P Gilbert, Yoshan Moodley
Journal: Molecular Biology and Evolution (2023)

The black rhinoceros (Diceros bicornis L.) is a critically endangered species historically distributed across sub-Saharan Africa. Hunting and habitat disturbance have diminished both its numbers and distribution since the 19th century, but a poaching crisis in the late 20th century drove them to the brink of extinction. Genetic and genomic assessments can greatly increase our knowledge of the species and inform management strategies. However, when a species has been severely reduced, with the extirpation and artificial admixture of several populations, it is extremely challenging to obtain an accurate understanding of historic population structure and evolutionary history from extant samples. Therefore, we generated and analyzed whole genomes from 63 black rhinoceros museum specimens collected between 1775 and 1981. Results showed that the black rhinoceros could be genetically structured into six major historic populations (Central Africa, East Africa, Northwestern Africa, Northeastern Africa, Ruvuma, and Southern Africa) within which were nested four further subpopulations (Maasailand, southwestern, eastern rift, and northern rift), largely mirroring geography, with a punctuated north-south cline. However, we detected varying degrees of admixture among groups and found that several geographical barriers, most prominently the Zambezi River, drove population discontinuities. Genomic diversity was high in the middle of the range and decayed toward the periphery. This comprehensive historic portrait also allowed us to ascertain the ancestry of 20 resequenced genomes from extant populations. Lastly, using insights gained from this unique temporal data set, we suggest management strategies, some of which require urgent implementation, for the conservation of the remaining black rhinoceros diversity.
Salient Measures of Hospitalist Workload
Authors: Marisha Burden, Lauren McBeth, Angela Keniston
Journal: JAMA Network Open (2023)

The ideal hospitalist workload and optimal way to measure it are not well understood.To obtain expert consensus on the salient measures of hospitalist workload.This qualitative study used a 3-round Delphi technique between April 5 and July 13, 2022, involving national experts within and external to the field. Experts included hospitalist clinicians, leaders, and administrators, as well as researchers with expertise in human factors engineering and cognitive load theory.Three rounds of surveys were conducted, during which participants provided input on the salient measures of hospitalist workload across various domains. In the first round, free-text data collected from the surveys were analyzed using a directed qualitative content approach. In the second and third rounds, participants rated each measure's relevance on a Likert scale, and consensus was evaluated using the IQR. Percentage agreement was also calculated.Seventeen individuals from 14 organizations, encompassing clinicians, leaders, administrators, and researchers, participated in 3 rounds of surveys. In round 1, participants provided 135 unique qualitative comments across 10 domains, with 192 unique measures identified. Of the 192 measures presented in the second round, 6 (3%) were considered highly relevant, and 25 (13%) were considered moderately relevant. In round 3, 161 measures not meeting consensus were evaluated, with 25 (16%) considered highly relevant and 95 (59%) considered moderately relevant. Examples of measures considered highly relevant included a patient complexity score and outcome measures such as savings from hospital days avoided and clinician turnover.In this qualitative study measuring hospitalist workload, multiple measures, including those quantifying work demands and the association of those demands with outcomes, were considered relevant for measuring and understanding workloads. The findings suggest that relying on traditional measures, such as productivity-related measures and financial measures, may offer an incomplete understanding of workloads and their association with key outcomes. By embracing a broader range of measures, organizations may be able to better capture the complexity and nuances of hospitalist work demands and their outcomes on clinicians, patients, and organizations.
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors
Authors: Pedro Marques, Paula Matias, Milton Packer, Joana T. Vieira, Francisco Vasques‐Nóvoa, Abhinav Sharma, Thomas A. Mavrakanas, Fernando Friões, João Pedro Ferreira
Journal: European Journal of Heart Failure (2023)
Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides
Authors: David M. Weiner, Olivia Pierog, Sima Rozati
Journal: JAMA Oncology (2023)

A 53-year-old woman with mycosis fungoides presented with hyperpigmentation of the oral mucosa. Examination of the mouth revealed multiple coalescing painless nonpruritic black macules and patches on the tongue, roof of the mouth, and buccal mucosa. What is your diagnosis?
Artificial intelligence and heart failure: A <scp>state‐of‐the‐art</scp> review
Authors: Muhammad Shahzeb Khan, Muhammad Sameer Arshad, Stephen J. Greene, Harriette G.C. Van Spall, Ambarish Pandey, Sreekanth Vemulapalli, Eric Perakslis, Javed Butler
Journal: European Journal of Heart Failure (2023)
Letter to the editor: Antimicrobial resistance data and treatment guidelines – challenges in the context of urine samples and mecillinam testing
Authors: Muna Abu Sin, Esther Wohlfarth, Anja Klingeberg, Tim Eckmanns, Michael Kresken, Evelyn Kramme, Guido Werner
Journal: Eurosurveillance (2023)

Preview this article: Letter to the editor: Antimicrobial resistance data and treatment guidelines – challenges in the context of urine samples and mecillinam testing, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/28/32/eurosurv-28-32-4-1.gif
Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism
Authors: Shiwan Hu, Qiyou Ding, Wei Zhang, Mengjiao Kang, Jing Ma, Linhua Zhao
Journal: Gut Microbes (2023)

A growing amount of evidence has supported that gut microbiota plays a vital role in the reproductive endocrine system throughout a woman's whole life, and gut microbial β-glucuronidase (gmGUS) is a key factor in regulating host estrogen metabolism. Moreover, estrogen levels also influence the composition as well as the diversity of gut microbiota. In normal condition, the gmGUS-estrogen crosstalk maintains body homeostasis of physiological estrogen level. Once this homeostasis is broken, the estrogen metabolism will be disturbed, resulting in estrogen-related diseases, such as gynecological cancers, menopausal syndrome, etc. together with gut microbial dysbiosis, which may accelerate these pathological processes. In this review, we highlight the regulatory role of gmGUS on the physical estrogen metabolism and estrogen-related diseases, summarize the present evidence of the interaction between gmGUS and estrogen metabolism, and unwrap the potential mechanisms behind them. Finally, gmGUS may become a potential biomarker for early diagnosis of estrogen-induced diseases. Regulating gmGUS activity or transplanting gmGUS-producing microbes shows promise for treating estrogen-related diseases.
Seroprevalence for Borrelia burgdorferi sensu lato and tick-borne encephalitis virus antibodies and associated risk factors among forestry workers in northern France, 2019 to 2020
Authors: Alexandra Septfons, Emma Rigaud, Laetitia Bénézet, Aurelie Velay, Laurence Zilliox, Lisa Baldinger, Gaëlle Gonzalez, Julie Figoni, Henriette de Valk, Gaëtan Deffontaines, Jean Claude Desenclos, Benoit Jaulhac
Journal: Eurosurveillance (2023)

BackgroundLyme borreliosis (LB) is the most common tick-borne disease (TBD) in France. Forestry workers are at high risk of TBD because of frequent exposure to tick bites.AimWe aimed to estimate the seroprevalence of Borrelia burgdorferi sensu lato and tick-borne encephalitis virus (TBEV) antibodies among forestry workers in northern France. We compared seroprevalence by geographical area and assessed factors associated with seropositivity.MethodsBetween 2019 and 2020, we conducted a randomised cross-sectional seroprevalence survey. Borrelia burgdorferi sl seropositivity was defined as positive ELISA and positive or equivocal result in western blot. Seropositivity for TBEV was defined as positive result from two ELISA tests, confirmed by serum neutralisation. We calculated weighted seroprevalence and adjusted prevalence ratios to determine association between potential risk factors and seropositivity.ResultsA total of 1,778 forestry workers participated. Seroprevalence for B. burgdorferi sl was 15.5% (95% confidence interval (CI): 13.9-17.3), 3.5 times higher in the eastern regions than in the western and increased with seniority and with weekly time in a forest environment. Seroprevalence was 2.5 times higher in forestry workers reporting a tick bite during past years and reporting usually not removing ticks rapidly. Seroprevalence for TBEV was 0.14% (95% CI: 0.05-0.42).ConclusionWe assessed for the first time seroprevalence of B. burgdorferi sl and TBEV antibodies among forestry workers in northern France. These results will be used, together with data on LB and tick-borne encephalitis (TBE) incidence and on exposure to tick-bites, to target prevention programmes.